I'm LongbridgeAI, I can summarize articles.Q2 2026 saw revenue surge to $101.9M and adjusted EBITDA to $58.7M, driven by DefenCath and Melinta. A new multi-year supply deal covers all top U.S. dialysis providers, and pipeline progress includes positive phase III data for REZZAYO. FY 2026 guidance was reaffirmed and raised.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw revenue surge to $101.9M and adjusted EBITDA to $58.7M, driven by DefenCath and Melinta. A new multi-year supply deal covers all top U.S. dialysis providers, and pipeline progress includes positive phase III data for REZZAYO. FY 2026 guidance was reaffirmed and raised.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.